Nitroprusside

Nitroprusside

Form: Intravenous (IV) injection

Strength: 50 mg/2 mL vial

Reference Brands: Nitropress®(US), Nitroprussiat Ferrlecit®(EU)

Category: Critical Care

Nitroprusside is a fast-acting vasodilator used in hypertensive emergencies and acute heart failure. Administered via IV infusion, it comes in 50 mg/2 mL vials as a lyophilized powder requiring dilution. Nitroprusside provides immediate blood pressure control by relaxing vascular smooth muscle. Available under brands like Nitropress® in the US and Nitroprussiat Ferrlecit® in the EU, it is widely used in critical care and surgical settings. Pharma B2B marketplaces offer bulk sourcing of GMP-compliant nitroprusside from certified manufacturers, ensuring consistent quality, global regulatory compliance, and secure supply for hospitals, ICUs, and emergency care providers

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details Get Enquiry
Insulin (IV)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details Get Enquiry
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details Get Enquiry
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.